News | June 16, 2023
PrecisionLife announces strategic CNS drug development collaboration with Nanopharmaceutics
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
Alpenglow has created an end-to-end 3D spatial biology solution including patented high-throughput 3D imaging
Advancing to IND-enabling studies with multiple drug candidates
The facility is among 12 centres established worldwide, and the first in Asia
It works with Pfizer to support more rapid innovation and improved clinical manufacturing operations to help develop tomorrow’s therapies
The goal for the project is the identification and optimization of anti-viral compounds.
We are building an AI-native operating system for pharma sales and distribution
The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process
The partnership covers the entire product lifecycle from early-stage development through commercialization
The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
Subscribe To Our Newsletter & Stay Updated
